Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of HB0043 in Healthy Adult Subjects
NCT06999083Phase 1Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0043 in psoriasis (7 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Percentage of subjects with drug related adverse events at 1200 hours. Started Jun 2025; status: completed.
02
Drugs
HB0043
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06999083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999083.